4SC 202

Drug Profile

4SC 202

Alternative Names: 4SC-202

Latest Information Update: 13 Apr 2017

Price : $50

At a glance

  • Originator Nycomed
  • Developer 4SC
  • Class Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action HDAC1 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Haematological malignancies
  • Preclinical Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 11 Apr 2017 Preclinical trials in Pancreatic cancer in Germany (PO) before April 2017
  • 11 Apr 2017 Pharmacodynamics data from a preclinical trial in Pancreatic cancer released by 4SC (PO)
  • 11 Apr 2017 4SC plans a clinical trial for Cancer (Second-line therapy or greater, Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top